What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.”In the company’s words, NCT04602754 on ClinicalTrials.gov
Other drugs for Dyslipidemia Associated With Type II Diabetes Mellitus
- ObicetrapibNewAmsterdam Pharma · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- SHR-1918Hengrui · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2026 | Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026